Cargando…

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

Systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown etiology, and the limited available therapeutic options for this disease, are frustrating to both clinicians and patients. However, recent advances in the understanding of disease mechanisms have given rise to numerous stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiesik-Szewczyk, E, Olesinska, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460634/
https://www.ncbi.nlm.nih.gov/pubmed/23055692
http://dx.doi.org/10.2147/BTT.S25407
_version_ 1782244961434992640
author Wiesik-Szewczyk, E
Olesinska, M
author_facet Wiesik-Szewczyk, E
Olesinska, M
author_sort Wiesik-Szewczyk, E
collection PubMed
description Systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown etiology, and the limited available therapeutic options for this disease, are frustrating to both clinicians and patients. However, recent advances in the understanding of disease mechanisms have given rise to numerous studies on specific approaches to SLE treatment. Rituximab, the first chimeric, mouse-human monoclonal antibody which is directed against CD20, seems to be a new therapeutic option. The purpose of this review is to explain the current clinical evidence on the therapeutic use of rituximab in adult SLE patients. Two randomized clinical trials with rituximab (the EXPLORER and LUNAR studies) failed to prove efficacy of this drug on SLE. Ongoing data analysis continues to explain the reasons behind why this treatment fails to work. However data from open source and observational studies contrast with clinical trials results. The global analysis of this data supports the off-label use of rituximab in subsets of SLE that are refractory to standard treatment.
format Online
Article
Text
id pubmed-3460634
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34606342012-10-09 B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab Wiesik-Szewczyk, E Olesinska, M Biologics Review Systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown etiology, and the limited available therapeutic options for this disease, are frustrating to both clinicians and patients. However, recent advances in the understanding of disease mechanisms have given rise to numerous studies on specific approaches to SLE treatment. Rituximab, the first chimeric, mouse-human monoclonal antibody which is directed against CD20, seems to be a new therapeutic option. The purpose of this review is to explain the current clinical evidence on the therapeutic use of rituximab in adult SLE patients. Two randomized clinical trials with rituximab (the EXPLORER and LUNAR studies) failed to prove efficacy of this drug on SLE. Ongoing data analysis continues to explain the reasons behind why this treatment fails to work. However data from open source and observational studies contrast with clinical trials results. The global analysis of this data supports the off-label use of rituximab in subsets of SLE that are refractory to standard treatment. Dove Medical Press 2012 2012-09-26 /pmc/articles/PMC3460634/ /pubmed/23055692 http://dx.doi.org/10.2147/BTT.S25407 Text en © 2012 Wiesik-Szewczyk and Olesinska, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Wiesik-Szewczyk, E
Olesinska, M
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_full B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_fullStr B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_full_unstemmed B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_short B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
title_sort b-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460634/
https://www.ncbi.nlm.nih.gov/pubmed/23055692
http://dx.doi.org/10.2147/BTT.S25407
work_keys_str_mv AT wiesikszewczyke bcelltargetedtherapyinsystemiclupuserythematosuspotentialofrituximab
AT olesinskam bcelltargetedtherapyinsystemiclupuserythematosuspotentialofrituximab